[1]
|
Heine, R.J., et al. (2006) Management of hyperglycaemia in type 2 diabetes. British Medical Journal, 333, 1200-1204. doi:10.1136/bmj.39022.462546.80
|
[2]
|
Cook, M.N., et al. (2005) Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care, 28, 995-1000. doi:10.2337/diacare.28.5.995
|
[3]
|
Holman, R., et al. (2008) Intensive glucose control in type 2 diabetes. New England Journal of Medicine, 359, 1577-1589. doi:10.1056/NEJMoa0806470
|
[4]
|
Rutten, G.E.H.M., et al. (2006) NHG-standaard diabetes mellitus type 2. Huisarts en Wetenschap, 49, 137-152.
|
[5]
|
Nathan, D., et al. (2009) Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetologia, 52, 17-30.
doi:10.1007/s00125-008-1157-y
|
[6]
|
Rubino, A., et al. (2007) Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: A population-based analysis in the UK. Diabetic Medicine, 24, 1412-1418. doi:10.1111/j.1464-5491.2007.02279.x
|
[7]
|
Cook, M., et al. (2007) Initial monotherapy with either metformin or sulphonylureas often fails to achieve maintain current glycaemic goals in patients with type 2 diabetes in UK primary care. Diabetic Medicine, 24, 350-358. doi:10.1111/j.1464-5491.2007.02078.x
|
[8]
|
Korytkowski, M. (2002) When oral agents fail: Practical barriers to starting insulin. International Journal of Obesity, 26, S18-S24. doi:10.1038/sj.ijo.0802173
|
[9]
|
Peyrot, M., et al. (2005) Resistance to insulin therapy among patients and providers: Results of the cross-sectional Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care, 28, 2673-2679.
doi:10.2337/diacare.28.11.2673
|
[10]
|
Tabaei, B.P., et al. (2004) Glycemia and the quality of well-being in patients with diabetes. Quality of Life Research, 13, 1153-1161.
doi:10.1023/B:QURE.0000031336.81580.52
|
[11]
|
Rubin, R. (2005) Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. American Journal of Medicine, 118, 27S-24S.
doi:10.1016/j.amjmed.2005.04.012
|
[12]
|
Lundkvist, J., et al. (2005) The economic and quality of life impact of hypoglycemia. European Journal of Health Economics, 6, 197-202.
|
[13]
|
Cryer, P.E. and Childs, B.P. (2002) Negotiating the barrier of hypoglycemia in diabetes. Diabetes Spectrum, 15, 20-27. doi:10.2337/diaspect.15.1.20
|
[14]
|
Polonsky, W., et al. (2005) Psychological insulin resistance in patients with type 2 diabetes: The scope of the problem. Diabetes Care, 28, 2543-2545.
doi:10.2337/diacare.28.10.2543
|
[15]
|
Wilson, M., et al. (2004) Treatment satisfaction after commencement of insulin in type 2 diabetes. Diabetes Research and Clinical Practice, 66, 263-267.
doi:10.1016/j.diabres.2004.04.010
|
[16]
|
Houlden, R., et al. (2007) Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of type 2 diabetes: The Canadian INSIGHT study. Diabetes Research and Clinical Practice, 78, 254-258. doi:10.1016/j.diabres.2007.03.021
|
[17]
|
Vinik, A., et al. (2007) Adding insulin glargine versus rosiglitazone. Health-related quality of life impact in type 2 diabetes. Diabetes Care, 30, 795-800.
doi:10.2337/dc06-1712
|
[18]
|
Hajos, T., et al. (2011) Initiation of insulin glargine in patients with type 2 diabetes in suboptimal glycaemic control positively impacts health-related quality of life. A prospective cohort study in primary care. Diabetic Medicine, 28, 1096-1102.
doi:10.1111/j.1464-5491.2011.03329.x
|
[19]
|
De Grauw, W.J.C., et al. (2001) Insulin therapy in poorly controlled type 2 diabetic patients: Does it affect quality of life? British Journal of General Practice, 51, 527-532.
|
[20]
|
De Sonnaville, J.J., et al. (1998) Well-being and symptoms in relation to insulin therapy in type 2 diabetes. Diabetes Care, 21, 919-924.
doi:10.2337/diacare.21.6.919
|
[21]
|
Redekop, W., et al. (2002) Health-related quality of life and treament satisfaction in Dutch patients with type 2 diabetes. Diabetes Care, 25, 458-463.
doi:10.2337/diacare.25.3.458
|
[22]
|
Goddijn, P., et al. (1999) Longitudinal study on glycaemic control and quality of life in patients with type 2 diabetes mellitus referred for intensified control. Diabetes Medicine, 16, 23-30.
doi:10.1046/j.1464-5491.1999.00002.x
|
[23]
|
Davis, T., et al. (2001) Effect of insulin therapy on quality of life in type 2 diabetes mellitus: The Fremantle Diabetes Study. Diabetes Research and Clinical Practice, 52, 63-71. doi:10.1016/S0168-8227(00)00245-X
|
[24]
|
Horvath, K., et al. (2007) Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews, 2, CD005613.
|
[25]
|
Hajos, T., et al. (2009) Switching from NPH to insulin glargine positively impacts on glycemic control and psychological well-being in suboptimally controlled type 2 diabetes patients. An observational study. Diabetes, 58, A537
|
[26]
|
Snoek, F.J., et al. (1996) The Dutch version of the hypoglycemia fear survey: Internal consistency and validity. Gedrag en Gezondheid, 24, 287-292.
|
[27]
|
Grootenhuis, P., et al. (1994) Development of a type 2 diabetes symptom checklist: A measure of symptom severity. Diabetic Medicine, 11, 253-261.
doi:10.1111/j.1464-5491.1994.tb00268.x
|
[28]
|
Arbuckle, R., et al. (2009) Psychometric evaluation of the Diabetes Symptom Checklist-Revised (DSC-R)-A Measure of Symptom Distress. Value Health, 12, 1168-1175. doi:10.1111/j.1524-4733.2009.00571.x
|
[29]
|
Bech, P., et al. (1996) The WHO (Ten) Well-Being Index: Validation in diabetes. Psychotherapy and Psychosomatics, 65, 183-190. doi:10.1159/000289073
|
[30]
|
Lowe, B., et al. (2004) Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians’ diagnoses. Journal of Affective Disorders, 78, 131-140.
doi:10.1016/S0165-0327(02)00237-9
|
[31]
|
Rubin, D.B. (1987) Multiple imputation for nonresponse in surveys. John Wiley & Sons, New York.
doi:10.1002/9780470316696
|
[32]
|
Rosenstock, J., et al. (2005) Reduced hypoglycemia risk with insulin glargine. A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care, 28, 950-955.
doi:10.2337/diacare.28.4.950
|
[33]
|
Mullins, P., et al. (2007) Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin glargine compared with Neutral Protamine Hagendorn insulin in type 1 and type 2 diabetes mellitus. Clinical Therapeutics, 29, 1607-1619.
doi:10.1016/j.clinthera.2007.08.020
|
[34]
|
Hermansen, K., et al. (2006) A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care, 29, 1269-1274.
doi:10.2337/dc05-1365
|
[35]
|
Rossetti, P., et al. (2008) Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. Archives of Physiology and Biochemistry, 114, 3-10.
doi:10.1080/13813450801900777
|
[36]
|
Rosenstock, J., et al. (2008) A randomised, 52 week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia, 51, 408-416.
doi:10.1007/s00125-007-0911-x
|
[37]
|
Swinnen, S., et al. (2010) A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled in oral glucose-lowering drugs. Diabetes Care, publish ahead of print, published online March 3, 2010.
|
[38]
|
Hollander, P., et al. (2008) A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clinical Therapeutics, 30, 1976-1987. doi:10.1016/j.clinthera.2008.11.001
|
[39]
|
Raskin, P., et al. (2009) Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 25, 542-548. doi:10.1002/dmrr.989
|
[40]
|
Swinnen, S., et al. (2011) Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews, 7, CD006383.
doi:10.1002/14651858.CD006383.pub2
|
[41]
|
Swinnen, S., et al. (2009) Higher dose requirements with insulin detemir in type 2 diabetes—Three cases and a review of the literature. Diabetes Research and Clinical Practice, 84, e24-e26. doi:10.1016/j.diabres.2009.02.009
|
[42]
|
Morris, A.D. (2003) Addressing dosing frequency in diabetes: A simple approach to improving adherence to therapy and clinical outcomes. Diabetes Educator, 29, 440-446. doi:10.1177/014572170302900309
|
[43]
|
Hajos, T., et al. (2011) Modest weight gain following insulin glargine initiation is not associated with decreased health-related quality of life (HRQoL) in type 2 diabetes. Diabetes, 60, A229.
|
[44]
|
Bech, P., Olsen, L.R., Kjoller, M. and Rasmussen, N.K. (2003) Measuring well-being rather than the absence of distress symptoms: A comparison of the SF-36 mental health subscale and the WHO-five well-being scale. International Journal of Methods in Psychiatric Research, 12, 85-91. doi:10.1002/mpr.145
|